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ABSTRACT
Most individuals infected with Helicobacter pylori have elevated levels of specific IgG antibodies, but only
in about two-thirds of cases does the IgA titre exceed the cut-off level. The aim of this study was to
determine whether H. pylori-infected subjects with elevated IgG levels would subsequently produce IgA
antibodies, and whether elevated IgA levels increased during infection. Paired sera were available from
336 adults who took part in a large population-based health survey in 1977–1980 and a follow-up study
on asthma and atopic diseases in 1997–1998 (series A). Data on paired sera from 224 adults who
participated in a population-based health survey in Vammala, Finland in 1973 and who gave a follow-
up blood sample in 1994 (series B) were also re-analysed. H. pylori IgG and IgA levels were determined
with commercially available (series A) and in-house (series B) enzyme immunoassays. Twenty-one
(35%) of the 60 subjects who initially had elevated levels of IgG antibodies only were found to be IgA-
positive at follow-up. In those subjects whose baseline and follow-up samples were IgG- and IgA-
positive, the median IgA levels increased by 48% and 22% in series A and B (p < 0.0001 and p 0.0241),
respectively, whereas the median IgG levels did not change significantly in either series. During
H. pylori infection, an increase in specific IgA was reflected by the increase in the number of responders
and by the rise in titres.
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INTRODUCTION
Helicobacter pylori infection is a chronic infection
that is acquired mainly in childhood [1–3]. The
prevalence rates of H. pylori antibodies increase
with age in all populations [4]. This has been
explained by the persistence of childhood infec-
tions with H. pylori, which have decreased
gradually since the early 1900s (a birth-cohort
phenomenon) [2,3,5,6]. Almost all H. pylori-
infected individuals have elevated levels of
specific IgG antibodies, but only in about two-
thirds of cases does the IgA titre exceed the
cut-off level [3,7]. Among infected individuals,
2–7% show an elevated IgA level alone [7,8].
Production of IgA antibodies has also been
associated with a CagA-positive infection [9],
which is associated in turn with an increased
risk of severe complications, including peptic
ulcer disease [10], atrophic gastritis and intesti-
nal metaplasia [11], and gastric cancer [12].
The prevalence rate of H. pylori IgA has been
reported to increase with age [13,14]. The present
study aimed to determine whether the increase in
the number of IgA-positive individuals with age
was a cohort phenomenon only, or whether
H. pylori-infected subjects who were initially
IgG-positive then proceeded to develop an IgA
response. The influence of new H. pylori
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infections was evaluated and the level of IgA in




The Social Insurance Institution organised a comprehensive
population-based health survey in Finland (Mini-Finland
Health Survey) during 1978–1980, following pilot studies
carried out in 1977 [15]. A sample of 8000 individuals,
representing all Finns aged ‡ 30 years, was studied. The
sampling method comprised a two-stage stratified cluster
design and the sample was self-weighting. In total, 7217
individuals (90% of the sample) participated in a basic
health examination, including collection of a blood sample.
Subsequently, 403 adults took part in a follow-up study
concerning asthma and atopic diseases two decades later
(range 17.7–20.1 years; mean 19.0 years) during 1997–1998
[16]. Of these, 139 adults either had asthma in the original
survey, or had developed asthma during the follow-up
period, while 264 adults served as controls. Cases and
controls were matched for gender, age and area of residence.
Among these 403 adults, paired serum samples were
available, stored at ) 20C, from 336 individuals (initial age
range, 30–58 years; median age, 44 years; 207 (61.6%)
females) for the present study (series A).
Series B
The present study also re-analysed data for paired sera from 224
adults who took part in a population-based health survey
during 1973 in Vammala, Finland, and who gave a follow-up
blood sample in 1994 (series B). Seroepidemiological findings on
H. pylori infection and on specific IgE, based on this material,
have been published previously [3,17]. Allergen-specific serum
IgE antibodies against birch and timothypollen, and cat anddog
dander allergens,weredeterminedwith the radioallergosorbent
test [17]. The paired sera, stored at) 20C and obtained from the
224 subjects (initial age range in 1973, 15–59 years; median age,
33 years; 131 (58.5%) females), had also been analysed for
antibodies toH. pylori. Of the nine IgG seroconverters, eight had
developed an IgA response, and of the eight IgG seroreverters,
all three subjects with elevated IgA antibodies also seroreverted
[3].
Serological methods
Paired sera from series A were tested for H. pylori IgG and
IgA antibodies using Pyloriset EIA-G III and Pyloriset
EIA-A III assay kits (Orion Diagnostica, Espoo, Finland).
Titres ‡ 30 were considered positive after local validation
(data not shown). With application of this threshold, the
sensitivity and specificity of the Pyloriset assays were 99%
and 90% for IgG, and 80% and 89% for IgA [18]. Paired
serum samples were tested in parallel on the same test
plates.
As reported previously [19], the cut-off titres for the
in-house enzyme immunoassays used in series B were 700
for IgG and 70 for IgA. The sensitivity and specificity for the
in-house enzyme immunoassays were 94% and 93% for IgG,
and 73% and 95% for IgA [3].
Statistics
The statistical significance of the increase in IgA titres was
examined with Wilcoxon’s signed rank pair test. The increase
in the number of IgA responders was evaluated with McNe-
mar’s test. Statistical analyses were performed using SPSS
v. 12.0 software (SPSS Inc., Chicago, IL, USA).
RESULTS
Prevalence rates of IgA and IgG antibodies
The prevalence rates of H. pylori IgA and IgG
increased with age in both series. The overall age-
adjusted IgA prevalence was 55% during both
1977–1980 and 1997–1998 in series A, and was
30% in 1973 and 33% in 1994 in series B. For
H. pylori IgG, the overall age-adjusted prevalence
rates were 65% and 59%, respectively, in series A,
and remained unchanged (45% and 46%) in
series B. There was no significant difference in
series B in the prevalence of H. pylori IgA between
subjects with and without allergen-specific IgE
(30% and 27%, respectively).
IgG seroconverters and seroreverters in the
Mini-Finland Study
In series A, seven individuals who were originally
antibody-negative had developed a positive IgG
response during the subsequent two decades, and
five had also become positive for IgA. The annual
rate of new infections was 0.1%. The number of
IgG seroreverters was 35. Among these, there was
a change in IgA status from positive to negative
for 15 individuals, while there was persisting IgA
positivity at follow-up, despite negative IgG
serology, in nine subjects.
Changes in IgA in subjects with a persisting
IgG response
Within the follow-up period, there was an
increase, although not statistically significant, in
the number of individuals with an elevated
H. pylori IgA response. Overall, one-third (15 of
29 in series A; six of 31 in series B) of the 60
individuals who initially had IgG only had
developed an IgA response that exceeded the
cut-off titre during the follow-up period (Table 1).
For the 197 individuals who showed elevated
IgG and IgA antibody titres in both samples (i.e.,
baseline and follow-up), the median IgA titres
increased by 48% (p < 0.0001) and 22% (p 0.0241)
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in series A and B, respectively. In contrast, the
changes in the median IgG titres () 1% in series
A; ) 18% in series B) were not significant
(Table 2). The number of IgA seroconverters
among individuals with a persisting positive
IgG response (15 of 40 in series A; six of 20 in
series B) was not significantly higher than that
found among the IgA seroreverters (nine of 149 in
series A; two of 59 in series B; p 0.1102) (Table 1).
DISCUSSION
The present study demonstrates that the increase
in the prevalence rate of H. pylori IgA antibodies
according to age [13,14] is not caused solely by the
birth-cohort phenomenon and seroconverters, but
is also associated with rising IgA titres during
chronic infection. In several subjects, the initial
normal IgA levels later rose above the cut-off
level, thus increasing the proportion of IgA-
seropositive subjects in older cohorts. In children,
an increase in both H. pylori IgG and IgA titres
has been observed [20]. The present findings
imply that the maturation of the IgA response,
indicated by rising IgA titres, still continues in
adulthood, whereas the increase in IgG titres in
children [20] has disappeared in adulthood. This
agrees with earlier studies showing that the
sensitivity of H. pylori IgA assays was lower than
the sensitivity of tests for IgG, especially in
younger age groups [18,20].
In series A, 2% of the initially antibody-negat-
ive subjects became IgG-positive during the
20-year follow-up period. This was close to the
reported IgG seroconversion rate of 4% in series
B, and the annual rate of new infections was quite
similar [3]. The proportion of seroreverters was
slightly higher in series A (10%) than in a
population within series B that had not been
treated actively with antimicrobial agents to cure
H. pylori infection. In series B, only 4% of the
initially antibody-positive subjects had an IgG
level that had fallen below the cut-off point
during the follow-up period [3].
In addition to newand curedH. pylori infections,
the prevalence rate ofH. pylori IgA was influenced
by changes in IgA response among thosewhowere
IgG-positive throughout follow-up. Although the
number of IgA seroconverterswas higher than that
of IgA seroreverters among subjects with a persist-
ing positive IgG response, the difference did not
reach statistical significance.
The use of frozen serum samples was based on
the fact that H. pylori antibodies tolerate multiple
cycles of freezing and thawing [21,22]. Ten cycles
of freezing and thawing of known H. pylori-
positive and -negative sera have no effect on the
positivity of either IgG or IgA [21], while three
thawings of sera have been reported to result in
an estimated maximal reduction of 1.3% in
sensitivity [22]. Thus, sera stored and thawed on
several occasions can be used reliably for longi-
tudinal research.
Although the selection (population vs. asthma
patients) and age distribution of the study groups
were different, and two different EIAs were used
for the two series, the changes in IgA antibody
titres were similar. In a separate study, which
included series A, no difference was found in the
prevalence of H. pylori IgA between subjects with
and without asthma, regardless of atopy (perso-
nal unpublished observations). Furthermore,
there was no significant difference in series B in
the prevalence of H. pylori IgA antibodies
between subjects with and without allergen-spe-
cific IgE. The sensitivity of the Pyloriset IgA assay
is higher than that of the in-house IgA assay (80%
and 73%, respectively), whereas the specificity of
the Pyloriset IgA assay is lower (89% and 95%,
respectively) [3,18]. However, the differences in
Table 1. IgA antibody status during Helicobacter pylori
infection in 268 subjects with a persisting positive IgG
response
IgA status
Number Proportion (%)Initial Follow-up
Negative Negative 39 14.5
Positive Positive 197 73.5
Negative Positive 21 7.8
Positive Negative 11 4.1
Table 2. Long-term changes in median IgG and IgA titresa
during Helicobacter pylori infection in 197 subjects with a













Initial 5500 180 2940 885
Follow-up 4500 220 2910 1310
Change of medians ) 18.2% + 22.2% ) 1.0% + 48.0%
p value for change
in mediansb
0.5000 0.0241 0.0932 < 0.0001
aIgG and IgA status were measured by Pyloriset EIA-GIII and -AIII (Orion
Diagnostica, Espoo, Finland) in the Mini-Finland Study, and by in-house IgG and
IgA enzyme immunoassays in the Vammala study.
bStatistical significance was examined by using Wilcoxon’s signed rank pair test.
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the overall age-adjusted IgA prevalences in the
present study were too distinct to be explained
solely by the number of false-positive samples.
The clinical importance of the IgA response is
underlined when considered in association with
earlier findings showing an association between
H. pylori IgA and gastric cancer [23], and also with
a CagA-positive infection [9]. As the H. pylori IgA
response may develop later in life, manyH. pylori-
infected young individuals may have IgG only,
although this does not exclude the possibility of
developing an IgA response subsequently. IgA
production, seen both as a greater number of
responders and in higher IgA titres, has been
reported to be elevated in children infected with a
CagA-positive strain as compared with children
infected with CagA-negative strains [24].
Individualswith aCagA-positive infection are at
a higher risk of developing severe complications
[10–12]. Thus, in subjects infected with a CagA-
positive strain, the gastric mucosa has shownmore
intense inflammatory changes than in subjects
infected with CagA-negative strains [24–26]. Since
the seroprevalence of CagA-positive H. pylori
infection has been found to decline more rapidly
than that of CagA-negative infection in the Finnish
population, especially among subjects aged
< 45 years [27], it will be of interest to see whether
this will affect the prevalence rate and clinical
importance of IgA antibodies in coming years.
In conclusion, the level of IgA increased during
persisting H. pylori infection. This was seen both
as an increased number of IgA responders and in
rising antibody titres. The maturation of the IgA
response in H. pylori infection, in contrast to the
IgG response, appeared to continue into adult-
hood. The mechanisms behind this phenomenon
remain to be studied.
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